S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
NASDAQ:GLYC

GlycoMimetics Stock Forecast, Price & News

$3.85
+0.09 (+2.39 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.77
Now: $3.85
$3.94
50-Day Range
$3.50
MA: $3.77
$4.24
52-Week Range
$1.82
Now: $3.85
$5.19
Volume810,430 shs
Average Volume611,919 shs
Market Capitalization$184.15 million
P/E RatioN/A
Dividend YieldN/A
Beta2.46
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist, which has completed Phase III clinical trial for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.
GlycoMimetics logo

MarketRank

Overall MarketRank

1.91 out of 5 stars

Medical Sector

67th out of 1,556 stocks

Pharmaceutical Preparations Industry

32nd out of 638 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLYC
CUSIPN/A
Phone240-243-1201
Employees57

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.56 per share

Profitability

Net Income$-57,890,000.00

Miscellaneous

Market Cap$184.15 million
Next Earnings Date2/26/2021 (Estimated)
OptionableOptionable
$3.85
+0.09 (+2.39 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GLYC News and Ratings via Email

Sign-up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions

How has GlycoMimetics' stock been impacted by COVID-19 (Coronavirus)?

GlycoMimetics' stock was trading at $2.94 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GLYC stock has increased by 31.0% and is now trading at $3.85.
View which stocks have been most impacted by COVID-19
.

Is GlycoMimetics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GlycoMimetics stock.
View analyst ratings for GlycoMimetics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than GlycoMimetics?

Wall Street analysts have given GlycoMimetics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but GlycoMimetics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is GlycoMimetics' next earnings date?

GlycoMimetics is scheduled to release its next quarterly earnings announcement on Friday, February 26th 2021.
View our earnings forecast for GlycoMimetics
.

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) announced its quarterly earnings data on Friday, November, 6th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.04. The biotechnology company had revenue of $1 million for the quarter.
View GlycoMimetics' earnings history
.

What price target have analysts set for GLYC?

3 brokerages have issued 1 year price targets for GlycoMimetics' shares. Their forecasts range from $15.00 to $15.00. On average, they anticipate GlycoMimetics' share price to reach $15.00 in the next twelve months. This suggests a possible upside of 289.6% from the stock's current price.
View analysts' price targets for GlycoMimetics
or view Wall Street analyst' top-rated stocks.

Are investors shorting GlycoMimetics?

GlycoMimetics saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 2,530,000 shares, an increase of 36.0% from the December 15th total of 1,860,000 shares. Based on an average trading volume of 585,000 shares, the short-interest ratio is presently 4.3 days. Approximately 6.7% of the company's shares are short sold.
View GlycoMimetics' Short Interest
.

Who are some of GlycoMimetics' key competitors?

What other stocks do shareholders of GlycoMimetics own?

Who are GlycoMimetics' key executives?

GlycoMimetics' management team includes the following people:
  • Ms. Rachel K. King, Pres, CEO & Director (Age 62, Pay $844.67k)
  • Dr. John L. Magnani, Sr. VP of Research & Chief Scientific Officer (Age 68, Pay $559.45k)
  • Dr. Helen M. Thackray, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 53, Pay $604.72k)
  • Mr. Brian M. Hahn, Sr. VP & CFO (Age 47)
  • Ms. Stephanie R. Irish, VP of Accounting (Age 50)
  • Mr. Henry Flanner, VP of Technical Operations
  • Mr. Christian Dinneen-Long, VP, Corp. Counsel & Corp. Sec.
  • Mr. Armand Girard, Chief Bus. Officer and Sr. VP of Strategy & Corp. Devel. (Age 52)

What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

How do I buy shares of GlycoMimetics?

Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GlycoMimetics' stock price today?

One share of GLYC stock can currently be purchased for approximately $3.85.

How big of a company is GlycoMimetics?

GlycoMimetics has a market capitalization of $184.15 million. The biotechnology company earns $-57,890,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis. GlycoMimetics employs 57 workers across the globe.

What is GlycoMimetics' official website?

The official website for GlycoMimetics is www.glycomimetics.com.

How can I contact GlycoMimetics?

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.